Cytarabine and azanucleoside DNA methyltransferase (DNMT) inhibitors are widely used in AML patients, which have been revealed to cause a substantial increase in ROS in both resting and leukemia cells and trigger cell cycle arrest and apoptosis [24, 25]. Here, DNMT1 is linked to acute myeloid leukemia.